COMPAZINE
LOE ApproachingNDAORALSYRUP
Approved
Dec 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COMPAZINE (prochlorperazine) is an oral syrup small-molecule antipsychotic approved in 1957 by GSK. It is primarily used as an antiemetic and for management of nausea, vomiting, and psychiatric conditions. The drug works as a dopamine antagonist in the central nervous system.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), indicating potential team consolidation and shift toward legacy brand management or generic transition support.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on COMPAZINE offers limited career advancement opportunities given the LOE-approaching lifecycle and minimal linked job openings. Roles focus on maximizing profitability and managing competitive erosion rather than innovation and growth.
Brand ManagerProduct Manager
Worked on COMPAZINE at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.